目的总结CDK4/6抑制剂治疗乳腺癌所致不良反应的相关护理证据,为临床实践提供循证依据。方法采用PIPOST问题开发工具构建循证问题,按照“6S”证据金字塔模型,遵循自上而下的原则,系统检索BMJ Best Practice、Up To Date、澳大利亚乔安...目的总结CDK4/6抑制剂治疗乳腺癌所致不良反应的相关护理证据,为临床实践提供循证依据。方法采用PIPOST问题开发工具构建循证问题,按照“6S”证据金字塔模型,遵循自上而下的原则,系统检索BMJ Best Practice、Up To Date、澳大利亚乔安娜布里格斯研究所循证卫生保健数据库、美国国立指南数据库、美国国立综合癌症网络、加拿大医学会临床实践指南网、苏格兰校际指南网、国际指南协作网、英国国家卫生与临床优化研究所、新西兰指南协作组网站、加拿大安大护理学会、Pub Med、Web of Science、Cochrane Library、Embase、中国期刊全文数据库、万方学术期刊全文数据库、医脉通等,检索时限为建库起至2023年12月31日。由2~4名研究者进行文献筛选、质量评价、证据提取及整合。结果最终纳入17篇文献,其中包含1篇临床决策、1篇指南、2篇专家共识、4篇meta分析、1篇随机对照试验、2篇系统评价、6篇原始研究。从用药前评估、用药观察、皮肤护理、胃肠道反应管理、多学科协作管理、心理干预6个方面总结出17条证据。结论本研究总结了CDK4/6抑制剂治疗乳腺癌所致不良反应的相关护理证据,可为临床护理实践提供参考,护理人员可结合患者的临床症状与实际需求,实施规范化、个体化的护理干预。展开更多
Breast cancer remains the primary cause of cancer-related mortality for women globally;therefore,further breakthroughs in treatment approaches are crucial.Palbociclib,ribociclib,and abemaciclib are among the Cyclin-de...Breast cancer remains the primary cause of cancer-related mortality for women globally;therefore,further breakthroughs in treatment approaches are crucial.Palbociclib,ribociclib,and abemaciclib are among the Cyclin-dependent kinase 4 and 6(CDK4/6)inhibitors that have become an innovative family of targeted therapy for hormone receptor-positive,Human Epidermal Growth factor receptor 2(HR+/HER2-)breast cancer.These inhibitors work by preventing the action of CDK4/6,which are crucial in the regulation of the cell cycle.Leading cancer cells to cell cycle arrest and undergo apoptosis.When these inhibitors are used with endocrine medicines like letrozole and fulvestrant,clinical trials lead positive impact in progression-free survival and,in a few cases,complete survival.However,despite their effectiveness,resistance mechanisms are primary and current acquired problems,requiring combined approaches with additional targeted medicines and continuous investigation into innovative therapeutic plans.To maintain patient compliance and quality of life,common side effects such as tiredness,gastrointestinal problems,and neutropenia need to be effectively managed.There is hopefulness for wider oncological applications as next-generation CDK inhibitor development and adaptive clinical trials continue to test their potential beyond breast cancer.CDK4/6 inhibitors continue to be a key part of breast cancer treatment as cancer biology advances,marking a major advancement towards more potent and customized cancer medicines.This review aims to provide current evidence on CDK4/6 inhibitors in HR+/HER2-breast cancer,highlighting their mechanisms,interaction with endocrine resistance,combination strategies,and emerging biomarkers guiding personalized therapy.展开更多
Objective To explore the correlation between chromosome 8 open reading frame 76(C8orf76)and cyclin-dependent kinase 4(CDK4)and the potential predictive effect of C8orf76 and CDK4 on the prognosis of colorectal cancer(...Objective To explore the correlation between chromosome 8 open reading frame 76(C8orf76)and cyclin-dependent kinase 4(CDK4)and the potential predictive effect of C8orf76 and CDK4 on the prognosis of colorectal cancer(CRC).Methods We constructed a protein-protein interaction network of C8orf76-related genes and analyzed the prognostic signatures of C8orf76 and CDK4.Clinicopathological features of C8orf76 and CDK4 were visualized using a nomogram.Results C8orf76 and CDK4 levels were positively correlated in two independent human CRC cohorts(n=83 and n=597).A consistent positive correlation was observed between C8orf76 and CDK4 expression in the CRC cell lines.The nomogram included prognostic genes(C8orf76 and CDK4)and pathological N and M stages.The concordance index(C-index)in our cohort was 0.776,which suggests that the ability of the indicators to predict the overall survival of patients with CRC in our cohort was strong.Conclusion We found that C8orf76 was positively correlated with CDK4 in both the cohorts as well as in CRC cell lines.Therefore,C8orf76 and CDK4 can be used as potential biomarkers to predict the prognosis of CRC.展开更多
文摘目的总结CDK4/6抑制剂治疗乳腺癌所致不良反应的相关护理证据,为临床实践提供循证依据。方法采用PIPOST问题开发工具构建循证问题,按照“6S”证据金字塔模型,遵循自上而下的原则,系统检索BMJ Best Practice、Up To Date、澳大利亚乔安娜布里格斯研究所循证卫生保健数据库、美国国立指南数据库、美国国立综合癌症网络、加拿大医学会临床实践指南网、苏格兰校际指南网、国际指南协作网、英国国家卫生与临床优化研究所、新西兰指南协作组网站、加拿大安大护理学会、Pub Med、Web of Science、Cochrane Library、Embase、中国期刊全文数据库、万方学术期刊全文数据库、医脉通等,检索时限为建库起至2023年12月31日。由2~4名研究者进行文献筛选、质量评价、证据提取及整合。结果最终纳入17篇文献,其中包含1篇临床决策、1篇指南、2篇专家共识、4篇meta分析、1篇随机对照试验、2篇系统评价、6篇原始研究。从用药前评估、用药观察、皮肤护理、胃肠道反应管理、多学科协作管理、心理干预6个方面总结出17条证据。结论本研究总结了CDK4/6抑制剂治疗乳腺癌所致不良反应的相关护理证据,可为临床护理实践提供参考,护理人员可结合患者的临床症状与实际需求,实施规范化、个体化的护理干预。
基金funded by School of Medical Sciences and Universiti Sains Malaysia。
文摘Breast cancer remains the primary cause of cancer-related mortality for women globally;therefore,further breakthroughs in treatment approaches are crucial.Palbociclib,ribociclib,and abemaciclib are among the Cyclin-dependent kinase 4 and 6(CDK4/6)inhibitors that have become an innovative family of targeted therapy for hormone receptor-positive,Human Epidermal Growth factor receptor 2(HR+/HER2-)breast cancer.These inhibitors work by preventing the action of CDK4/6,which are crucial in the regulation of the cell cycle.Leading cancer cells to cell cycle arrest and undergo apoptosis.When these inhibitors are used with endocrine medicines like letrozole and fulvestrant,clinical trials lead positive impact in progression-free survival and,in a few cases,complete survival.However,despite their effectiveness,resistance mechanisms are primary and current acquired problems,requiring combined approaches with additional targeted medicines and continuous investigation into innovative therapeutic plans.To maintain patient compliance and quality of life,common side effects such as tiredness,gastrointestinal problems,and neutropenia need to be effectively managed.There is hopefulness for wider oncological applications as next-generation CDK inhibitor development and adaptive clinical trials continue to test their potential beyond breast cancer.CDK4/6 inhibitors continue to be a key part of breast cancer treatment as cancer biology advances,marking a major advancement towards more potent and customized cancer medicines.This review aims to provide current evidence on CDK4/6 inhibitors in HR+/HER2-breast cancer,highlighting their mechanisms,interaction with endocrine resistance,combination strategies,and emerging biomarkers guiding personalized therapy.
基金supported by a grant from National Natural Science Foundation of China(No.82203623)2022&2023 Hebei introduction of foreign expert intelligence projects(Nos.YZ202201&YZ202305)+1 种基金Hebei Natural Science Foundation(Nos.H2020206374 and H2021206306)Hebei Clinical Medicine Excellent Talents Project of Province(No.LS202001).
文摘Objective To explore the correlation between chromosome 8 open reading frame 76(C8orf76)and cyclin-dependent kinase 4(CDK4)and the potential predictive effect of C8orf76 and CDK4 on the prognosis of colorectal cancer(CRC).Methods We constructed a protein-protein interaction network of C8orf76-related genes and analyzed the prognostic signatures of C8orf76 and CDK4.Clinicopathological features of C8orf76 and CDK4 were visualized using a nomogram.Results C8orf76 and CDK4 levels were positively correlated in two independent human CRC cohorts(n=83 and n=597).A consistent positive correlation was observed between C8orf76 and CDK4 expression in the CRC cell lines.The nomogram included prognostic genes(C8orf76 and CDK4)and pathological N and M stages.The concordance index(C-index)in our cohort was 0.776,which suggests that the ability of the indicators to predict the overall survival of patients with CRC in our cohort was strong.Conclusion We found that C8orf76 was positively correlated with CDK4 in both the cohorts as well as in CRC cell lines.Therefore,C8orf76 and CDK4 can be used as potential biomarkers to predict the prognosis of CRC.
